Navigation Links
Denovo Biopharma plans to launch a Global Phase 3 Trial of DB102 (Enzastaurin) in Diffuse Large B-cell Lymphoma

SAN DIEGO, Feb. 16, 2017 /PRNewswire/ -- Denovo Biopharma LLC, a leading company in precision medicine announces the plan to initiate a biomarker driven global phase 3 clinical trial for its lead drug DB102 as a first line therapy for diffuse large B-cell lymphoma (DLBCL) patients this year.

DB102 (Enzastaurin) is a PKCß inhibitor originally developed by Eli Lilly and for which Denovo has acquired Worldwide rights.  DB102 showed promising clinical results in the DLBCL induction setting in a Phase 2 trial, but did not meet the primary endpoint in a Phase 3 study.  Denovo subsequently conducted an in-depth analysis of the DB102 clinical data and identified that a subset of patients showed improved survival.   Using our unique biomarker platform, Denovo has successfully discovered a novel biomarker, DGM1 (Denovo Genomic Marker 1), for DB102.  The DGM1 positive patients exhibited significantly improved overall survival over DGM1 negative patients in DB102 treatment group in both phase 2 and 3 studies.  Based on this encouraging finding, Denovo plans to conduct a Randomized, Double-Blind, Placebo-Controlled, global Phase 3 Study in DGM1 positive DLBCL patients in the US and China.

"The successful discovery of the DGM1 biomarker is a major breakthrough for Denovo Biopharma, and has validated again the advantage of the Denovo's biomarker discovery platform," said Dr. Wen Luo, CEO of Denovo Biopharma.  "Denovo's unique precision medicine technology and business model allows us to unlock the hidden value in many of the drugs which have failed in late stage trials.  If the DGM1 driven DB102 clinical trial is successful, as a first-line medication, it is expected to have a significant positive impact on patient outcomes and also to establish Enzastaurin as a significant new therapy for the treatment of DLBCL. "

Denovo also opened a new clinical center in Beijing, China last year to complement the existing center in San Diego.  Isabel Han, head of Denovo's clinical operations in Beijing, said "China will play a very important role in the biomarker driven DB102 trial, and we have successfully submitted the IND application to the China FDA.  We are building an experienced clinical team to support all Denovo's global clinical trials."

About DB102
DB102 (formerly Enzastaurin) is an orally available investigational small molecule, serine/threonine kinase inhibitor of the PKC beta and AKT pathways and has been studied in more than 3,000 patients across a range of solid and hematological tumor types.  DLBCL occurs in approximately 25,000 patients annually in the U.S. Enzastaurin has received orphan drug designation from the FDA and EMA.

About Denovo Biopharma
Denovo Biopharma is a privately-held biotechnology company that provides novel and proprietary biomarker approaches to advance drug development, including re-evaluating medicines that have failed in general patient populations by stratifying the responders for the original indication. The company offers the first platform and algorithm for de novo genomic biomarker discovery using archived clinical samples.  This technology may be especially useful for compounds with suboptimal late-stage trial results.  By identifying biomarkers correlated with patients' responses to drug candidates retrospectively, Denovo enables the design and execution of follow-on clinical trials in targeted patient populations while optimizing efficacy, safety and tolerability. For additional information please visit

Robert Little, Chief Business Officer
Denovo Biopharma LLC


To view the original version on PR Newswire, visit:

SOURCE Denovo Biopharma
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Syngenta Chose NRGenes DeNovoMAGICTM to Map 12 Genomes in Only Eight Months
2. Denovo Biopharma Licenses Late-Stage Neuroscience Drug From Lilly For Development As A Personalized Medicine
3. Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine
4. Benitec Biopharma to present expanded data set from pivotal data in hepatitis B virus (HBV) in vivo model at International Liver Meeting in Shanghai, China
5. Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering
6. Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2017
7. CTI BioPharma to Present at the BIO CEO & Investor Conference
8. How These Drug Makers Stocks are Faring? -- Provectus Biopharma, TherapeuticsMD, Novartis, and Tonix Pharma
9. Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2017 on February 9, 2017
10. Regen BioPharma Begins Optimization of NR2F6 Small Molecule Modulators
11. CTI BioPharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors
Post Your Comments:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):